Live
Endpoints NewsPost-Hoc Live: Makary's out at FDA and what comes nextCellThe immunoproteasome disturbs neuronal metabolism and drives neurodegeneration in multiple sclerosisFierceBiotechNovartis, amid reorg, cuts ‘select number’ of biomedical research rolesPharmaVoiceSanofi’s vaccine bump; the new FDA commishEndpoints NewsAardvark's next move after clinical hold; Alumis' verdict on Acelyrin assetFierceBiotechWhy Model Medicines needs to ‘discover new colors’ in its AI drug discovery questBioPharma DiveIndia’s pharma industry is going global. But can it catch up to China?BioWorldSanofi identifies YAP1/TEAD and TAZ/TEAD interaction inhibitorsBioWorldCSPC Megalith Biopharmaceutical discloses new CDCP1-targeting ADCsBioWorldAntelope Therapeutics patents new antibody-drug conjugates for cancerBioWorldHangzhou Institute of Medicine discovers new CDK2/cyclin E1 inhibitorsBioWorldNew KRAS mutant inhibitors reported in Université de Montréal patent
FierceBiotech Mar 31, 2026

AstraZeneca’s Strensiq successor misses phase 3 rare disease goal, denting market expansion plan

AstraZeneca’s Strensiq successor misses phase 3 rare disease goal, denting market expansion plan

Original
Body unavailable. Use the original source.